Institut Pasteur-ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2022

  1. Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis

    Nature Communications, Vol. 13, Núm. 1

  2. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

    Journal of Experimental Medicine, Vol. 219, Núm. 7

2021

  1. Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies

    Cell Reports Medicine, Vol. 2, Núm. 5

  2. Functional heterogeneity of mammalian IFITM proteins against HIV-1

    Journal of Virology, Vol. 95, Núm. 18

  3. Revisiting an IgG Fc Loss-of-Function Experiment: The Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity

    mBio, Vol. 12, Núm. 5

  4. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation

    EMBO Journal, Vol. 40, Núm. 24

2020

  1. A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

    Science Translational Medicine, Vol. 12, Núm. 559

  2. Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells

    EMBO Reports, Vol. 21, Núm. 2

  3. Flow cytometry analysis of HIV-1 env conformations at the surface of infected cells and virions: Role of Nef, CD4, and SERINC5

    Journal of Virology, Vol. 94, Núm. 6

  4. Syncytia formation by SARS-CoV-2-infected cells

    EMBO Journal, Vol. 39, Núm. 23

2019

  1. Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01

    Cell Host and Microbe, Vol. 26, Núm. 5, pp. 623-637.e8

2018

  1. Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity

    Cell Reports, Vol. 23, Núm. 9, pp. 2568-2581

  2. HIV-1 cell-to-cell transmission and broadly neutralizing antibodies

    Retrovirology, Vol. 15, Núm. 1